Immunex Corporation

GPTKB entity

Predicate	Object
gptkbp:instance_of	gptkb:biotechnology
gptkbp:acquired_by	gptkb:Amgen
gptkbp:acquisition	$16 billion
gptkbp:acquisition_year	gptkb:2002
gptkbp:ceo	gptkb:David_W._Scott gptkb:Robert_A._Bradway gptkb:Kevin_Sharer
gptkbp:clinical_trial	gptkb:Crohn's_disease gptkb:ulcerative_colitis gptkb:rheumatoid_arthritis gptkb:ankylosing_spondylitis psoriasis
gptkbp:dissolved	gptkb:2002
gptkbp:employees	1,200 (2001)
gptkbp:founded	gptkb:1981
gptkbp:founded_in	gptkb:Seattle,_Washington
gptkbp:founder	gptkb:Dr._John_C._Lechleiter
gptkbp:headcount	1,500 (2002)
gptkbp:headquarters	gptkb:Seattle gptkb:Seattle,_Washington
https://www.w3.org/2000/01/rdf-schema#label	Immunex Corporation
gptkbp:industry	gptkb:biotechnology
gptkbp:key_people	gptkb:David_W._Scott gptkb:Robert_A._Bradway gptkb:Kevin_Sharer
gptkbp:location	gptkb:United_States
gptkbp:notable_products	gptkb:Enbrel gptkb:Neupogen gptkb:Kineret
gptkbp:notable_work	immune system modulation TNF inhibitors
gptkbp:parent_company	gptkb:Amgen_Inc.
gptkbp:partnerships	gptkb:Johnson_&_Johnson gptkb:Bristol-Myers_Squibb gptkb:Pfizer gptkb:Eli_Lilly_and_Company gptkb:Glaxo_Smith_Kline
gptkbp:products	gptkb:Enbrel gptkb:Neupogen gptkb:Kineret
gptkbp:revenue	$1.5 billion (2001)
gptkbp:subsidiary	gptkb:Amgen_Inc.
gptkbp:trade	gptkb:AMGN
gptkbp:type	gptkb:public_company
gptkbp:website	www.immunex.com
gptkbp:bfsParent	gptkb:Amgen
gptkbp:bfsLayer	4